Lushang Freda PharmaceuticalLtd Future Growth

Future criteria checks 4/6

Lushang Freda PharmaceuticalLtd is forecast to grow earnings and revenue by 30% and 15.3% per annum respectively. EPS is expected to grow by 29.8% per annum. Return on equity is forecast to be 10.4% in 3 years.

Key information

30.0%

Earnings growth rate

29.8%

EPS growth rate

Real Estate earnings growth	30.4%
Revenue growth rate	15.3%
Future return on equity	10.4%
Analyst coverage	Good
Last updated	20 May 2024

Recent future growth updates

Recent updates

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Apr 16

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Mar 28

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Feb 27

Earnings and Revenue Growth Forecasts

SHSE:600223 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6,381	585	128	983	8
12/31/2025	5,569	487	53	578	10
12/31/2024	4,738	377	2,467	1,850	8
3/31/2024	4,197	233	213	418	N/A
12/31/2023	4,579	303	263	474	N/A
9/30/2023	7,817	130	-127	98	N/A
6/30/2023	10,590	47	84	350	N/A
3/31/2023	12,741	108	1,263	1,442	N/A
12/31/2022	12,951	45	832	998	N/A
9/30/2022	14,543	13	3,070	3,273	N/A
6/30/2022	13,131	240	4,103	4,293	N/A
3/31/2022	12,140	342	5,970	6,250	N/A
12/31/2021	12,363	362	6,567	6,848	N/A
9/30/2021	12,929	729	7,473	7,700	N/A
6/30/2021	14,137	710	7,719	7,944	N/A
3/31/2021	13,915	662	5,543	5,712	N/A
12/31/2020	13,615	639	4,291	4,448	N/A
9/30/2020	10,316	572	4,680	4,841	N/A
6/30/2020	9,817	482	39	174	N/A
3/31/2020	10,307	364	-4,831	-4,759	N/A
12/31/2019	10,289	345	-3,367	-3,307	N/A
9/30/2019	10,373	222	-5,546	-5,516	N/A
6/30/2019	10,159	195	-2,295	-2,262	N/A
3/31/2019	9,261	184	3,184	3,222	N/A
12/31/2018	8,821	162	2,062	2,095	N/A
9/30/2018	10,105	166	1,120	1,207	N/A
6/30/2018	8,694	159	1,489	1,571	N/A
3/31/2018	8,476	129	278	360	N/A
12/31/2017	8,287	128	N/A	1,637	N/A
9/30/2017	7,576	102	N/A	3,215	N/A
6/30/2017	7,909	98	N/A	-1,495	N/A
3/31/2017	7,370	94	N/A	-1,127	N/A
12/31/2016	7,646	92	N/A	-2,468	N/A
9/30/2016	7,151	107	N/A	-4,768	N/A
6/30/2016	5,870	101	N/A	-1,056	N/A
3/31/2016	6,118	103	N/A	-1,723	N/A
12/31/2015	5,864	112	N/A	-1,798	N/A
9/30/2015	5,109	166	N/A	-991	N/A
6/30/2015	6,365	205	N/A	-1,002	N/A
3/31/2015	5,908	207	N/A	-1,042	N/A
12/31/2014	5,682	206	N/A	-2,363	N/A
9/30/2014	6,387	287	N/A	-2,457	N/A
6/30/2014	5,790	273	N/A	-2,511	N/A
3/31/2014	5,477	272	N/A	-2,356	N/A
12/31/2013	5,293	263	N/A	-1,088	N/A
9/30/2013	4,874	296	N/A	-989	N/A
6/30/2013	4,125	258	N/A	-343	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600223's forecast earnings growth (30% per year) is above the savings rate (2.9%).

Earnings vs Market: 600223's earnings (30% per year) are forecast to grow faster than the CN market (23.1% per year).

High Growth Earnings: 600223's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600223's revenue (15.3% per year) is forecast to grow faster than the CN market (14% per year).

High Growth Revenue: 600223's revenue (15.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600223's Return on Equity is forecast to be low in 3 years time (10.4%).

Lushang Freda PharmaceuticalLtd Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Price target decreased to CN¥12.27

Price target decreased to CN¥12.87

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.13 in 1Q 2023)

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Lushang Life Services Co., Ltd. (SEHK:2376) agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) for RMB 4.9 million.

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Investor sentiment deteriorates as stock falls 16%

Lushang Freda Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New major risk - Financial position

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Dividend sustainability

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates

Price target decreased to CN¥12.27

Third quarter 2022 earnings released: CN¥0.033 loss per share (vs CN¥0.19 profit in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.23 in 2Q 2021)

Price target decreased to CN¥12.87

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥16.16

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.17 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.18 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥16.10

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.06 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.34 in FY 2019)

Lushang Health Industry Development Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥14.15

New 90-day high: CN¥12.58

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.21

Market bids up stock over the past week

Third quarter earnings released

Lushang Health Industry Development Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥9.66

Earnings released

New 90-day high - CN¥15.60

Lushang Health Industry Development Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies